Leerink Partnrs also issued estimates for Regeneron Pharmaceuticals’ Q2 2025 earnings at $8.22 EPS, Q3 2025 earnings at $9.62 EPS, Q4 2025 earnings at $9.56 EPS, FY2025 earnings at $34.47 EPS ...

Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $762.00 to $834. ...

Regeneron stock tumbled Tuesday after the biotech giant reported a major revenue miss due to light sales of its eye drug Eylea.

A comprehensive examination of how financial experts perceive Regeneron Pharmaceuticals is ... Neutral | $759.00|$940.00 | |David Risinger |Leerink Partners |Raises |Outperform | $834.00|$762. ...

Laboratory operator Quest Diagnostics beat Wall Street estimates for first-quarter profit on Tuesday, helped by robust demand for its diagnostic tests.

Evergreen Capital Management boosted its Regeneron stake by 362.9%, snatching up 3,030 more shares and flexing some serious ...

Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...

Regeneron Pharmaceuticals (REGN) reported its first-quarter 2025 earnings, revealing a miss on both earnings and revenue expectations. The company posted earnings per share (EPS) of $8.22, falling ...